deltatrials
Recruiting PHASE2 INTERVENTIONAL 2-arm NCT04889716

CAR-T Followed by Bispecific Antibodies

Phase II Study of Dual Targeting of CD19 and CD20 Antigens Using Sequential CD19-directed CAR-T Cells Followed by Mosunetuzumab or Glofitamab in Relapsed or Refractory Diffuse Large B-cell or Transformed Follicular Lymphomas

Sponsor: Abramson Cancer Center at Penn Medicine

Conditions DLBCL - Diffuse Large B Cell Lymphoma Large B-cell Lymphoma
Interventions glofitamab mosunetuzumab obinutuzumab
Updated 13 times since 2021 Last updated: Feb 11, 2025 Started: Nov 5, 2021 Primary completion: Jun 30, 2026 Completion: Jun 30, 2027
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on DLBCL - Diffuse Large B Cell Lymphoma and Large B-cell Lymphoma, this trial is actively recruiting participants. The trial is conducted by Abramson Cancer Center at Penn Medicine and has accumulated 13 data snapshots since 2021. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jun 2021 – ~Sep 2021 · 3 months · monthly snapshot~Sep 2021 – ~Nov 2021 · 2 months · monthly snapshot~Nov 2021 – ~Jan 2022 · 2 months · monthly snapshot~Jan 2022 – ~Sep 2022 · 8 months · monthly snapshot~Sep 2022 – ~Apr 2023 · 7 months · monthly snapshot~Apr 2023 – ~Jun 2023 · 2 months · monthly snapshot~Jun 2023 – ~Jan 2024 · 7 months · monthly snapshot~Jan 2024 – ~Jul 2024 · 6 months · monthly snapshot~Jul 2024 – ~Aug 2024 · 31 days · monthly snapshot~Aug 2024 – ~Sep 2024 · 31 days · monthly snapshot~Sep 2024 – ~Jan 2025 · 4 months · monthly snapshot~Jan 2025 – ~Mar 2025 · 59 days · monthly snapshot~Mar 2025 – present · 18 months · monthly snapshot

Change History

13 versions recorded

  1. Mar 2025 — Present [monthly]

    Recruiting PHASE2

  2. Jan 2025 — Mar 2025 [monthly]

    Recruiting PHASE2

  3. Sep 2024 — Jan 2025 [monthly]

    Recruiting PHASE2

  4. Aug 2024 — Sep 2024 [monthly]

    Recruiting PHASE2

  5. Jul 2024 — Aug 2024 [monthly]

    Recruiting PHASE2

▶ Show 8 earlier versions

  1. Jan 2024 — Jul 2024 [monthly]

    Recruiting PHASE2

  2. Jun 2023 — Jan 2024 [monthly]

    Recruiting PHASE2

  3. Apr 2023 — Jun 2023 [monthly]

    Recruiting PHASE2

  4. Sep 2022 — Apr 2023 [monthly]

    Recruiting PHASE2

  5. Jan 2022 — Sep 2022 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  6. Nov 2021 — Jan 2022 [monthly]

    Not Yet Recruiting PHASE2

  7. Sep 2021 — Nov 2021 [monthly]

    Not Yet Recruiting PHASE2

  8. Jun 2021 — Sep 2021 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Abramson Cancer Center at Penn Medicine
  • Genentech, Inc.
Data source: Abramson Cancer Center at Penn Medicine

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations